If you would like to ask our webinar guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.
Not sure it would be worth them sending a nurse out to your premises for just 10 tests .
Tiptree- Only 3 companies can offer this, Roche , Abbott and ourselves.
CE marked (certified to meet EU requirements) as of 01 May 2020 based on testing that demonstrated 100% sensitivity (ability to detect COVID-19 antibodies) and 99.8% specificity (ability to rule out the presence of COVID-19 antibodies)
At this rate it will turn blue
So pipeline of over £160 million which could well be acheivable and using CF's metric of valuing the company of 2 to 3 times revenue, this could have a market cap of £450 million in next 12 months.
Jimzi - i can confirm that i heard CF did say they lease the property at Whitechappel , but on competitive terms, i can't tell you which interview because he has done quite a few now in the last year.
Link to CF on newstalk
https://www.newstalk.com/podcasts/highlights-from-the-hard-shoulder/irish-businesses-benefiting-pandemic
So say 20k tests a week at £50 profit per test after cost of test, nurses to take test, delivery to lab and results back to customer
is about a million quid a week.
CF keeps telling us that we are the world leaders and that there are very few companies in the world who can do what we do, so if that is the case then the valuation metric he keeps using of 2 - 3 times revenue which other CRO's are valued at who cant do what we do is plainly wrong. it should be much higher.
is the government chief advisor on antibody testing, he has only just stood down from sitting on the board of directors of Roche who have just got government contract. Level playing field ? i don't think so !
https://en.wikipedia.org/wiki/John_Bell_(physician)
Virtual rep Is this a new revenue stream for the company or was it always there and i missed it
https://www.openorphan.com/our-businesses/open-orphan#open-orphan-virtual-rep
presentation from last night
https://www.youtube.com/watch?v=IO-N_NT71a0
Open Orphan’s rapid growth continues with Covid-19 antibody test deal (ORPH)
11 MAY 2020 | Tom Rodgers
Shares in the Anglo-Irish rare drug company Open Orphan (LSE:ORPH) have been flying recently and should continue to move higher following the release of a new deal today.
Open Orphan will provide a new UK Covid-19 antibody test by partnering with Swiss pharma firm Quotient (NASDAQ:QTNT). Quotient has an antibody microarray system called MosaiQ, a specialist tool used to detect thousands of DNA expressions at the same time.
Quotient has entered into an exclusive contract with Open Orphan subsidiary hVIVO to support COVID-19 antibody testing in the UK.
“This collaboration is uniquely positioned to leverage our combined expertise, and helps address the large need for antibody testing in the UK and beyond.” said Quotient CEO Franz Walt.
ORPH started 2020 in reasonable shape, with shares trading at a cheap 4.85p. Things really started to take off just before Covid-19 lockdowns hit the world, with chairman Cathal Friel pushing through a series of deals detailing up to $7.7m in revenue, all realised this year.
That includes a $3.5m US human challenge study contract for respiratory viruses revealed in early May and a $3.2m March contract with a European biotech firm.
Executive chairman Cathal Friel noted:
“We are delighted to exclusively partner with Quotient Limited to bring fast and accurate COVID-19 antibody testing to the UK. Open Orphan plc, via our subsidiary hVIVO, has industry leading scientific and laboratory capability and the MosaiQ™ system’s best in class COVID-19 antibody testing performance makes the system a natural addition to our state-of-the-art virology laboratory in London.
“There is clear demand for Covid-19 antibody testing and we will be making testing available as a standalone offering. We will also utilise the testing capability to screen volunteers for our industry-leading range of human challenge studies.”
Open Orphan has blown past our early May price target of 10p and we are now raising our conservative target for the end of next quarter to 20p.
The shares are now changing hands for 13p and in our opinion should be re-rated higher shortly.
CF will have plenty to talk about in today's sharesoc presentation.
No worries on money , at least £4m in the bank, plus the 2 recent deals amounting to £7m was for 30% to be paid upfront.
This test blows ODX's test out of the water, first in class, gold standard , C.E mark, ready to roll. 100% sensitivity and 99.8% specificity , blimey doesn't get much better than that. Results in 35 minutes. Subsequent results occur every 24 seconds thereafter.
No wonder they needed another broker !
studies show that the flu vaccine actually makes you more susceptible to coronavirus, and there may be reasons for that. It's been speculated that there may be coronavirus contamination in the flu vaccines flu vaccines that are derived from chicken cells or dog kidney cells .
Guess what flu-v is synthetic , so is immune from this type of contamination.
Bottom third of this article.
https://www.facebook.com/permalink.php?id=339299132933393&story_fbid=1282441768619120
Interesting read, bottom third of article deals with inteferon beta 1a
https://www.facebook.com/permalink.php?id=339299132933393&story_fbid=1282441768619120
Gabriel - I am pretty shore that the shares that CF owns are locked in for 3 years from IPO date.